Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,007 Cr
verified against source
Revenue YoY
12.5%
reported change
EBITDA
₹435 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fortis Healthcare reported a strong Q4 FY25 with consolidated revenue of INR 2,007 crore (+12.5% YoY) and EBITDA margin of 21.7% (+40bps YoY). Hospital revenue grew 14.2% to INR 1,701 crore, driven by 9% ARPOB growth and occupancy improvement to 69%. The diagnostic business (Agilus) saw margin expansion to 18% (gross basis) despite flattish revenue. Management guided for ~2% margin expansion in FY26 for hospitals, supported by brownfield bed additions (~1,000 beds) and operational efficiencies. Key risks include slower ramp-up of new beds (Manesar) and ongoing legal costs (~1% of EBITDA).
Colored figures show movement against the previous available record.
Guidance to track
- Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
- Management guided for ~200bps margin expansion in the hospital business for FY26, similar to the improvement seen in FY25.
- Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.
- Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.
Risks flagged
- The large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
- Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
- Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
- International patient revenue growth of 17% may not sustain due to geopolitical tensions, though management expects stable contribution.
Key quotes
- We expect the margin to grow from the current level. Similar growth you can expect in the forthcoming years also, like 2% growth we have seen in the current financial year. Similar margin expansion growth we are expecting next financial year.
- We are aiming around 70-71% occupancy level at the overall level. Because this brownfield expansion is on the existing facility, and these hospitals anyway are operating at 80% type of occupancy level. I think we will not be facing any challenge in occupancy side.
- We have not considered that when we say that we are expecting about 2% of increase in our profitability profile. These hospitals are important statistically for the long term, but in the short term, whatever guidance has been given is not considering that these hospitals have come to a 20-plus category.
Research modules